Recent News

• 10.01.2025 - Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
• 10.01.2025 - Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
• 09.29.2025 - CLYM116 and the IgA Nephropathy (IgAN) Opportunity
• 09.29.2025 - CLYM116 and the IgA Nephropathy (IgAN) Opportunity
• 09.29.2025 - Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
• 09.29.2025 - Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
• 09.16.2025 - Stifel Virtual Immunology and Inflammation Forum
• 09.16.2025 - Stifel Virtual Immunology and Inflammation Forum
• 09.16.2025 - Stifel Virtual Immunology and Inflammation Forum
• 09.16.2025 - Stifel Virtual Immunology and Inflammation Forum

Recent Filings

• 10.01.2025 - 3 Initial statement of beneficial ownership of securities
• 10.01.2025 - 8-K Current report
• 10.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.29.2025 - EX-99.1 EX-99.1
• 09.29.2025 - 8-K Current report
• 09.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors